Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Therapeutics

Background:

• 5-azacytidine (5AC) and decitabine (DAC) are FDA-approved DNA hypomethylating agents for myelodysplastic syndrome.
• Both drugs are known to induce histone modifications influencing gene expression.
• Despite structural similarities, their distinct effects on histone PTMs warrant investigation.

Purpose of the Study:

• To compare the effects of 5AC and DAC on histone acetylation and methylation.
• To investigate differences in histone posttranslational modifications (PTMs) induced by 5AC and DAC.

Main Methods:

• Mass spectrometry to analyze 95 histone PTMs in leukemia cells treated with 5AC or DAC.
• ChIP-Seq to compare genome-wide H3K9 acetylation changes induced by both drugs in AML patient cells.

Main Results:

• Both 5AC and DAC induced diverse histone PTMs across various histone isoforms.
• Distinct differences in histone methylation and acetylation patterns were observed between 5AC and DAC treatments.
• 5AC significantly altered H3K9 acetylation at 925 genes, compared to 182 genes for DAC, with minimal overlap.

Conclusions:

• 5AC and DAC induce significantly different histone PTM profiles, challenging their interchangeability.
• The precise mechanisms driving these distinct histone PTM changes require further elucidation.
• Potential modulation of histone-modifying enzyme activity or expression may underlie observed differences.